Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

Novo Nordisk

Status and phase: Completed; Phase 4

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: repaglinide; Drug: glyburide

Study type: Interventional

Funder types: Industry

Identifiers

NCT01605773

AGEE-2137

Details and patient eligibility

About

This trial is conducted in the United States of America (USA). The aim of this trial is to compare the effect of repaglinide on postprandial lipemia in subjects with type 2 diabetes.

Enrollment: 51 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Newly diagnosed patients with type 2 diabetes currently treated with diet and exercise alone (HbA1c below 10%)
• Subjects with type 2 diabetes treated with sulphonylurea (HbA1c below 8.5%)
• Males or non-pregnant, non-lactating females
• Subjects should have normal renal function

Exclusion criteria

• Type 1 or other specific causes of diabetes
• Marked symptomatic diabetes
• Uncontrolled treated/untreated hypertension
• Known or suspected allergy to the trial products or related products

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

51 participants in 2 patient groups

repaglinide

Experimental group

Treatment:

Drug: repaglinide

glyburide

Active Comparator group

Treatment:

Drug: glyburide